Sai Life Sciences IPO (Sai Life Sciences Limited IPO)
Sai Life Sciences IPO open for bidding on 11th December 2024 and ends on 13th December 2024.
Sai Life Sciences Limited, headquartered in Hyderabad, India, is a leading player in the pharmaceutical and biotechnology sector. The company specializes in Contract Research, Development, and Manufacturing Organization (CRDMO) services, offering end-to-end solutions to global innovators. With a robust focus on quality and innovation, it caters to a wide range of therapeutic areas, driving advancements in healthcare.
Founded in 1999, Sai Life Sciences has evolved from its origins to become a trusted partner for pharmaceutical giants worldwide. The company boasts a state-of-the-art R&D and manufacturing infrastructure, supported by a team of skilled scientists. Its strategic locations and certifications ensure global delivery standards.
The company’s commitment to sustainability and innovation is reflected in its investments in green manufacturing technologies and compliance with global regulatory standards. Sai Life Sciences is poised to capitalize on growing demands for CRDMO services, driven by its strong industry reputation.
For more details refer to Sai Life Sciences IPO RHP and Sai Life Sciences IPO Pulse Score
Sai Life Sciences IPO Details
| IPO Date | 11th December 2024 to 13th December 2024 |
| Listing Date | 18th December 2024 |
| Face Value | ₹1 per share |
| Price Band | ₹522 to ₹549 per share |
| Lot Size | 27 Shares |
| Total Issue Size | [•] shares (aggregating up to ₹3,042.62 Cr) |
| Fresh Issue | [•] shares (aggregating up to ₹950.00 Cr) |
| Offer for Sale | 3,81,16,934 shares of ₹1 (aggregating up to ₹2,092.62 Cr) |
| Issue Type | Book Built Issue IPO |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | <50% |
| NII | >15% |
| bNII | 10% |
| sNII | 5% |
| Retail | >35% |
Sai Life Sciences IPO Timeline
| IPO Open | 11th December 2024 |
| IPO Close | 13th December 2024 |
| Basis Of Allotment | 16th December 2024 |
| Initiation of Refunds | 17th December 2024 |
| Credit of Shares to Demat | 17th December 2024 |
| Listing Date | 18th December 2024 |
Fundamentals
Data as of 30th September 2024
| Market Cap | ₹11,418.63 Cr | P/E Ratio- Pre IPO | 126.42 |
| RoNW* | 2.68% | P/E Ratio- Post IPO | 203.82 |
| RoCE* | 3.90% | P/B Ratio | 10.18 |
| Debt to Equity | 0.73 | PAT Margin | 4.15% |
Note: P/E Ratio -Pre IPO is calculated based on Pre-issue Shareholding and FY Earnings of March 2024. P/E Ratio- Post IPO is calculated based on post-issue shareholding and annualized FY earnings for September 2024. RoCE and RoNW are for six-month period ended September 30, 2024
Sai Life Sciences IPO Objectives
The company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company; and
- General corporate purposes.
Leave a Reply